Los Angeles Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Los Angeles Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-42,049	Closed	-$624K	–	1531
2021 Q3	$624K	Sell	42,049 -2,210	-5%	-$35.4K	﹤0.01%	954
2021 Q2	$884K	Buy	44,259 +16,506	+59%	+$327K	﹤0.01%	909
2021 Q1	$641K	Sell	27,753 -12,264	-31%	-$342K	﹤0.01%	1100
2020 Q4	$988K	Buy	40,017 +24,287	+154%	+$805K	﹤0.01%	951
2020 Q3	$652K	Sell	15,730 -4,989	-24%	-$229K	﹤0.01%	985
2020 Q2	$993K	Buy	20,719 +5,739	+38%	+$443K	﹤0.01%	855
2020 Q1	$943K	Hold	14,980	–	–	0.01%	723
2019 Q4	$1.86M	Buy	14,980 +7,580	+102%	+$679K	0.01%	667
2019 Q3	$491K	Buy	7,400 +4,353	+143%	+$292K	﹤0.01%	992
2019 Q2	$242K	Sell	3,047 -20	-0.7%	-$1.79K	﹤0.01%	1245
2019 Q1	$343K	Buy	+3,067	New	+$335K	﹤0.01%	1170
2014 Q3	–	Sell	-2,877	Closed	-$681K	–	1182
2014 Q2	$681K	Buy	+2,877	New	+$758K	0.01%	789

Other funds holding ICPT

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Los Angeles Capital Management's ICPT Position: Q4 2021 in Review

Los Angeles Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2021, closing a stake of 42,049 shares — an estimated $624K sold.

Los Angeles Capital Management first reported a position in ICPT in Q2 2014 and held it in 12 quarters. The position peaked at $1.86M in Q4 2019. 147 funds tracked by Wall St. Rank hold ICPT as of Q4 2021.

Los Angeles Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Los Angeles Capital Management sold 42,049 Intercept Pharmaceuticals, Inc. shares in Q4 2021, an estimated $624K.
Los Angeles Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 12 quarters.
Los Angeles Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $1.86M in Q4 2019.
147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2021.

Based on Los Angeles Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.